News
DOACs offered after heart valve surgery despite absence of data
March 9, 2021
Use of direct oral anticoagulants following heart valve surgery is occurring despite relative contraindications, but expert doubts its clinical significance.
News
RECOVERY trial of COVID-19 treatments stops colchicine arm
March 8, 2021
Recruitment was halted for lack of efficacy in patients hospitalized with the disease.
News
MIS-C follow-up proves challenging across pediatric hospitals
March 8, 2021
First came the challenge of figuring out the best treatment regimen for patients with MIS-C. Then physicians had to think about follow-up.
News
Heart failure redefined with new classifications, staging
March 8, 2021
Heart failure terminology gets a landmark reno, with a new universal definition, revised stages of development and progression, and updated LVEF classifications.
News
Late-window stroke thrombolysis not linked to clot migration
March 3, 2021
This is the first randomized controlled study to assess the effect of thrombolysis on clot migration and accessibility in an extended time window.
News
Thirteen percent of patients with type 2 diabetes have major ECG abnormalities
March 2, 2021
ECGs from more than 8,000 Dutch patients with type 2 diabetes, most without known cardiovascular disease, show that major abnormalities are not unusual.
News
New-onset arrhythmias low in COVID-19 and flu
February 26, 2021
Overall, incidence of AF/AFL and new onset AF/AFL was similar in COVID-19 vs. influenza. Mortality in those with arrhythmias also increased to a similar extent in both diseases.
News
Myocardial injury seen on MRI in 54% of recovered COVID-19 patients
February 25, 2021
Two months after discharge, 54% of hospitalized COVID-19 patients with troponin elevation showed signs of myocardial injury on MRI, some of which was likely pre-existing, the authors say.
News
New light cast on type 2 MI aims to sharpen diagnosis, therapy
February 23, 2021
A large survey of type 2 MI, triggered when myocardial oxygen demand outstrips supply, points to confusion hindering its diagnosis and treatment and reveals the rarity of revascularization.
News
More from DAPA-HF: Dapagliflozin quickly reduces heart failure events
February 22, 2021
Secondary analysis of DAPA-HF showed dapagliflozin significantly cut CV deaths or worsening heart failure within 28 days on treatment.